BusinessLine·3 min read·medium
Novo Nordisk India rolls-out a once-weekly basal insulin Awiqli
P
PT Jyothi Datta
✦AI Summary
Novo Nordisk has launched Awiqli, a once-weekly basal insulin for diabetes patients, in the Indian market. The product aims to simplify treatment regimens, though medical experts advise caution regarding its real-world application for Type 1 diabetes.
Danish healthcare company Novo Nordisk is rolling out its Awiqli – a weekly once basal insulin, for adults with Type 1 or Type 2 diabetes mellitus, in India. The product reduces the insulin regimen from once-daily to once-weekly – or from 365 shots to 52.
healthsciencebusiness
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in